 Valneva SE NASDAQ: VALN and IDT Biologika have announced their collaboration to produce Valnevas inactivated COVID-19 vaccine candidate VLA2001. It follows last weeks announcement that Valneva signed an Advance Purchase Agreement with the European Commission to supply up to 60 million doses of VLA2001 over two years. 